TD Cowen analyst Tyler Van Buren lowered the firm’s price target on Soleno Therapeutics (SLNO) to $85 from $120 and keeps a Buy rating on the shares. The firm said they delivered a strong Q4 generating $190MM of revenue from only 9 months of Vykat XR sales, and finished 2025 profitably. Management reaffirmed a strong commercial trajectory for 2026, with roughly 1K new start forms expected in the next 9-12 months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics CFO Mackaness to retire, Fulk to succeed
- Soleno Therapeutics Announces New Chief Financial Officer Appointment
- Soleno Therapeutics: Strong Early Vykat XR Traction, Rapid Market Penetration, and Expanding Growth Opportunities Support Buy Rating
- Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year
- SLNO Upcoming Earnings Report: What to Expect?